Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718680 | 0.91 | KDM4E (0.34) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL718897 | 0.86 | ABCG2 (0.35) | L3MBTL1 | |
| SCHEMBL718396 | 0.85 | DGAT1 (0.37) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL718137 | 0.81 | KDM4E (0.36) | DGAT1KDM4EMAPTP2RX3L3MBTL1 | |
| SCHEMBL720091 | 0.81 | GABRA1 (0.39) | MAPTL3MBTL1 | |
| SCHEMBL719057 | 0.79 | DGAT1 (0.42) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL718710 | 0.78 | KDM4E (0.34) | DGAT1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL717092 | 0.76 | NPC1 (0.37) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL721152 | 0.76 | DGAT1 (0.38) | DGAT1SOAT2SOAT1DGAT2KDM4E | |
| SCHEMBL3399846 | 0.75 | CASP3 (0.41) | MAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | DGAT1 869/4885SOAT2 606/4885SOAT1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.